文献速递骨质疏松与代谢性骨病

雷洛昔芬与阿仑膦酸钠对去卵巢兔每日人甲状旁腺激素(1-34)序贯治疗后非酶胶原交联与骨强度的影响

Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
PubMed 文献 · Osteoporos Int · 2016-10-29

研究在去卵巢兔中比较每日人甲状旁腺激素(1-34)治疗后序贯使用雷洛昔芬或阿仑膦酸钠对非酶胶原交联、骨量和骨强度的影响。雷洛昔芬序贯治疗改善生物力学性能并降低非酶胶原交联,阿仑膦酸钠序贯治疗改善生物力学性能但无胶原交联改善。

要点

  • 去卵巢兔每日hPTH(1-34)后序贯雷洛昔芬或阿仑膦酸钠均增加皮质厚度、最大载荷、最大应力和总BMD。
  • 仅雷洛昔芬序贯组降低小梁骨AGE、戊糖苷和同型半胱氨酸含量并增加韧性和断裂能。
  • 阿仑膦酸钠序贯组增加刚度和弹性模量,但对非酶胶原交联AGEs无影响。

核心结论

  • 结果提示hPTH(1-34)后序贯抗骨吸收药物(雷洛昔芬和阿仑膦酸钠)对去卵巢兔的骨量和生物力学性能有有益影响。

研究设计与样本

  • 7月龄雌性新西兰白兔去卵巢3个月后,给予溶媒或hPTH(1-34)(8 μg/kg/天)每日一次共5个月。
  • hPTH(1-34)治疗后的动物分为两组,分别口服雷洛昔芬(10 mg/kg,每日)或皮下注射阿仑膦酸钠(100 μg/kg,每周两次)共5个月。
  • 评估股骨骨密度(BMD)、骨结构参数、胶原中晚期糖基化终产物(AGE)含量及骨力学参数(含固有参数)。

主要发现

  • hPTH/RLX和hPTH/ALN序贯治疗均增加干骺端远端总BMD、皮质厚度、最大载荷和最大应力,并降低骨干内膜面。
  • 仅hPTH/RLX治疗降低小梁骨AGE、戊糖苷和同型半胱氨酸含量,并增加韧性和断裂能。
  • hPTH/ALN治疗增加刚度和弹性模量,但对非酶胶原交联AGEs无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study investigated the effects of raloxifene and alendronate to follow parathyroid hormone (PTH) on bone collagen and biomechanical properties in ovariectomized rabbits. Sequential treatments of raloxifene and alendronate after hPTH(1-34) treatment improved biomechanical properties with and without bone collagen improvement, respectively. INTRODUCTION: The standard sequential treatment to follow human parathyroid hormone (hPTH) (1-34) therapy for osteoporosis has yet to be determined. The objective of this study was to compare the effects of raloxifene and alendronate treatments to follow daily hPTH(1-34) treatment on non-enzymatic collagen cross-links, bone mass, and bone strength in ovariectomized (OVX) rabbits. METHODS: From 3 months after ovariectomy, seven month-old female New Zealand white rabbits were given either vehicle or hPTH(1-34) (8 μg/kg/day), once daily for 5 months. After hPTH(1-34) treatment, the hPTH(1-34)-treated animals were divided into two groups, and given raloxifene (10 mg/kg, daily) orally or alendronate (100 μg/kg, twice weekly) subcutaneously for 5 months. We evaluated bone mineral density (BMD), bone structural parameters, advanced glycation end product (AGE) content in collagen, and bone mechanical parameters including intrinsic parameters in the femur. RESULTS: Raloxifene (hPTH/RLX) and alendronate (hPTH/ALN) to follow hPTH(1-34) increased cortical thickness, maximum load, and maximum stress and decreased endocortical surface in the diaphysis, in addition to increasing total BMD in the distal metaphysis. Decreased trabecular AGE, pentosidine, and homocysteine contents and increased toughness and breaking energy were noted with hPTH/RLX treatment only. With hPTH/ALN treatment, no effects on non-enzymatic collagen cross-link AGEs were noted although increases in stiffness and elastic modulus were observed. CONCLUSION: These results suggest that sequential treatments with hPTH(1-34) and antiresorptive drugs (raloxifene and alendronate) have a beneficial effect on bone mass and biomechanical properties in OVX rabbits.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kimura S, Saito M, Kida Y, et al. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration. Osteoporos Int. 2016. PMID: 27796444. doi:10.1007/s00198-016-3812-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。